Inventor · disambiguated record
Ulrich Kronthaler
Also filed as: KRONTHALER ULRICH
5 granted patents·8 pending applications·65 citations·filing 2007–2021
80Inventor score
Top patents by PatentIndex Score
13 records- 0191US8283319B2Therapeutic application of Kazal-type serine protease inhibitorsSCHULTE STEFAN·Filed 2008·Granted Oct 9, 2012·33 cites·17 claims
- 0288US8575104B2Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-lifeWEIMER THOMAS·Filed 2009·Granted Nov 5, 2013·18 cites·27 claims
- 0384US8765915B2Modified coagulation factor VIIa with extended half-lifeWEIMER THOMAS·Filed 2007·Granted Jul 1, 2014·8 cites·13 claims
- 0474US9107902B2Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disordersKRONTHALER ULRICH·Filed 2008·Granted Aug 18, 2015·5 cites·8 claims
- 0568US9290561B2Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-lifeWEIMER THOMAS·Filed 2013·Granted Mar 22, 2016·1 cites·31 claims
- 0656US2014356346A1MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFECSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 0755US2022119471A1Glycoprotein with reduced acetylation rate of sialic acid residuesHEXAL AG·Filed 2021·Application pending·0 cites
- 0851US2011044993A1Method for the prevention and treatment of cancer by inhibition of gpviKRONTHALER ULRICH·Filed 2009·Application pending·0 cites
- 0949US2017080061A1MODIFIED COAGULATION FACTOR VIIa WITH EXTENDED HALF-LIFECSL BEHRING GMBH·Filed 2016·Application pending·0 cites
- 1044US2016151484A1Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drugHEXAL AG·Filed 2014·Application pending·0 cites
- 1141US2012039901A1Method for the prevention and treatment of cancer by inhibition of gpviKRONTHALER ULRICH·Filed 2011·Application pending·0 cites
- 1237US2019177385A1Glycoprotein with reduced acetylation rate of sialic acid residuesHEXAL AG·Filed 2017·Application pending·0 cites
- 1329US2012148557A1Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disordersKRONTHALER ULRICH·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →